Mebeverine

Oral
Gastrointestinal tract spasm, Irritable bowel syndrome

Paralytic ileus.

Patient w/ cardiac disorders (e.g. heart block). Renal and hepatic impairment. Pregnancy and lactation.

Dizziness, headache, GI disturbances, insomnia, anorexia, decreased heart rate, hypersensitivity (e.g. urticaria, erythematous rash, angioedema).

Symptoms: CNS excitability. Management: Symptomatic and supportive treatment. Gastric lavage may be considered in case of multiple intoxication or if discovered w/in approx 1 hr.

Description: Mebeverine is an antispasmodic agent which exerts direct action on the GI smooth muscle w/o affecting normal gut motility. The exact mechanism is unknown, but multiple mechanisms might contribute to its local effect in the GI tract, e.g. a decrease in ion channel permeabilities, blockade of norepinephrine reuptake, a local anaesth effect, changes in water absorption and weak anti-muscarinergic and phosphodiesterase inhibitory effect.
Pharmacokinetics:
Absorption: Rapidly absorbed from the GI tract. Time to peak plasma concentration: 1-3 hr.
Distribution: Plasma protein-binding: 75% to albumin.
Metabolism: Completely metabolised via hydrolysis to form veratric acid and mebeverine alcohol.
Excretion: Via urine (95% as metabolites).

Store below 30°C.

Antispasmodics

A03AA04 - mebeverine ; Belongs to the class of synthetic anticholinergics, esters with tertiary amino group. Used in the treatment of functional bowel disorders.

Anon. Mebeverine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 15/01/2016.

Buckingham R (ed). Mebeverine Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 15/01/2016.

Joint Formulary Committee. Mebeverine Hydrochloride. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 15/01/2016.